$EOLS

RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook • Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Re

Evolus said it expanded its partnership with Symatese to commercialize the Estyme injectable hyaluronic acid gel collection in Canada, Australia, and New Zealand. The deal, first announced in 2023, is expected to begin commercialization in 2028. Evolus also said it will hold exclusive rights in markets where it sells Jeuveau and Nuceiva. Shares were about $6.04.

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme ® in Canada, Australia, and New Zealand Establishes a complementary injectable hyaluronic acid (HA) gel portfolio alongside Jeuveau ® and Nuceiva ® across all Evolus commercial markets Further leverages Ev

Evolus Inc. said it signed an exclusive licensing and distribution deal with Swiss firm IBSA to develop and commercialize Profhilo in the U.S. Evolus will manage U.S. regulatory development and commercialization after approval. Profhilo is an injectable skin treatment launched in Europe in 2015 that stimulates collagen. Evolus shares were about $6.90.

Evolus (NASDAQ:EOLS) said it signed an exclusive licensing and distribution agreement with IBSA to develop and commercialize Profhilo, an injectable skin-quality product, in the United States. Evolus will handle U.S. regulatory development and commercialization. The deal has no upfront payments and uses a transfer-price model, and Evolus said it will not affect its 2026 or 2028 outlook.

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. eols-20260707 0001570562 false 0001570562 2026-07-07 2026-07-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. eols-20260611 0001570562 false 0001570562 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Evolus Inc. presented comprehensive clinical data for its Evolysse hyaluronic acid filler line, featuring its proprietary Cold-X™ Technology, and its Jeuveau neuromodulator. The company highlighted strong efficacy and safety profiles for both product lines in various aesthetic indications, including statistical superiority for Evolysse Form against a comparator. Evolus also discussed an extra-strength Jeuveau formulation and outlined its commercial roadmap for upcoming product launches, reinforcing its dual-product strategy and positive market outlook.

Evolus Inc. reported mixed first-quarter results, exceeding revenue expectations with a 7% increase to $73.1 million, but also posting a wider net loss of 16 cents compared to an anticipated 11-cent loss. The aesthetics company, known for its product Jeuveau, reaffirmed its full-year revenue guidance of $327 million to $337 million, representing 10% to 13% growth. Following the announcement, Evolus shares saw a slight rise in after-hours trading.